Holen Sie sich die Stockscreener-App
99.96
0.31%
0.31
Schlusskurs vom Vortag:
$99.65
Offen:
$99.78
24-Stunden-Volumen:
705.95K
Relative Volume:
0.55
Marktkapitalisierung:
$6.53B
Einnahmen:
$1.54B
Nettoeinkommen (Verlust:
$233.56M
KGV:
29.69
EPS:
3.3669
Netto-Cashflow:
$348.64M
1W Leistung:
+0.22%
1M Leistung:
-0.84%
6M Leistung:
+31.35%
1J Leistung:
+89.71%
1-Tages-Spanne:
$99.69
$100.07
1-Wochen-Bereich:
$99.31
$100.07
52-Wochen-Spanne:
$49.67
$111.86
Lantheus Holdings Inc Stock (LNTH) Company Profile
Firmenname
Lantheus Holdings Inc
Sektor
Telefon
978 671-8001
Adresse
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
99.96 | 6.51B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-12-12 | Hochstufung | Truist | Hold → Buy |
| 2025-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2025-08-12 | Herabstufung | Truist | Buy → Hold |
| 2024-12-18 | Eingeleitet | Goldman | Buy |
| 2024-09-03 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-07-10 | Bestätigt | JMP Securities | Mkt Outperform |
| 2023-12-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-12-04 | Eingeleitet | TD Cowen | Outperform |
| 2023-09-29 | Eingeleitet | William Blair | Outperform |
| 2023-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-11-30 | Eingeleitet | SVB Leerink | Outperform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-05-09 | Eingeleitet | B. Riley Securities | Buy |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2021-02-01 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-29 | Fortgesetzt | Jefferies | Buy |
| 2019-08-16 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2017-11-02 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-11-08 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-09-23 | Fortgesetzt | Credit Suisse | Neutral |
| 2016-02-24 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-12-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2015-09-30 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2015-07-20 | Eingeleitet | Credit Suisse | Outperform |
| 2015-07-20 | Eingeleitet | Jefferies | Buy |
| 2015-07-20 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2015-07-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-20 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Lantheus Holdings Inc Aktie (LNTH) Neueste Nachrichten
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
CMS Grants Transitional Pass-Through Payment Status to Lantheus (LNTH) PYLARIFY TruVu Injection - GuruFocus
Starting Oct. 1, Lantheus's prostate cancer scan qualifies for separate Medicare payment in hospital outpatient care. - Stock Titan
Lantheus Holdings, Inc. (LNTH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Total equity of Lantheus Holdings Inc – HAN:0L8 - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SoundThinking, Inc. (Nasdaq – SSTI), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corpor - mykxlg.com
Lantheus Investor Asks Court To Halt 'Unfair' $8B Curium Deal - Law360
Lantheus doses first patient in prostate cancer imaging trial By Investing.com - Investing.com Australia
Lantheus (LNTH) Begins Patient Dosing in SPARROW Trial for Prost - GuruFocus
Lantheus doses first patient in prostate cancer imaging trial - Investing.com
A patient receives an experimental prostate cancer scan; the later phase is expected to enroll about 400. - Stock Titan
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com - Investing.com India
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval - Yahoo Finance
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value - Stocktwits
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval - Yahoo Finance
Lantheus stock trades at USD 99.72 after FDA approval - AD HOC NEWS
FDA approves Lantheus’ Bravnetsa for GEP-NETs - dotmed.com
FDA approval for Lantheus’ Bravnetsa - The Pharma Letter
Lantheus Holdings, Inc. (LNTH) Stock Forecasts - Yahoo! Finance Canada
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - The Daily Tribune News
Curium Resets FTC Clock On $8B Lantheus Take-Private Deal - Law360
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally - Yahoo Finance
3 Reasons LNTH is Risky and 1 Stock to Buy Instead - Yahoo Finance
Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote - Mugglehead Investment Magazine
Lantheus wins final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate( for GEP-NETs - app.dealroom.co
LNTH Looks 11.3% Overvalued on GF Value™ After FDA Approval - GuruFocus
Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs - marketscreener.com
Lantheus Says Curium Resubmits Antitrust Filing for Merger - moomoo.com
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors By Investing.com - Investing.com Australia
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors - Investing.com India
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs - marketscreener.com
A radioactive cancer treatment becomes the first approved through the FDA’s abbreviated drug pathway - Stock Titan
The Technical Signals Behind (LNTH) That Institutions Follow - Stock Traders Daily
Lantheus Holdings stock faces a new Curium review window - AD HOC NEWS
LNTH Looks 11.3% Overvalued on GF Value™ - GuruFocus
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A Healthcare Powerhouse with a 7.15% Potential Upside - DirectorsTalk Interviews
Lantheus Holdings, Inc. (LNTH): Investor Outlook On A Potential 7.47% Upside - DirectorsTalk Interviews
(LNTH) Risk Channels and Responsive Allocation - Stock Traders Daily
LNTH, ITGR and CZR Deals Face Investor Scrutiny - stl.news
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc.LNTH - Business Wire
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Entities Hold 20.9% Stake in Radiopharm Theranostics (NASDAQ: RADX) Including Significant Options - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Lantheus (NASDAQ: LNTH) holders to vote on cash buyout with potential bonus payout - Stock Titan
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring Growth Potential in the Healthcare Sector - DirectorsTalk Interviews
Lantheus alpha therapy, CATX director, sells $131k in stock By Investing.com - Investing.com Australia
Finanzdaten der Lantheus Holdings Inc-Aktie (LNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantheus Holdings Inc-Aktie (LNTH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 10% Owner |
Sep 03 '26 |
Sale |
3.11 |
80,783 |
250,896 |
11,440,513 |
| Lantheus Alpha Therapy, LLC | 10% Owner |
Sep 02 '26 |
Sale |
3.11 |
42,129 |
131,219 |
11,521,296 |
| Lantheus Holdings, Inc. | 10% Owner |
Sep 01 '26 |
Sale |
3.12 |
35,769 |
111,574 |
11,563,425 |
| Lantheus Holdings, Inc. | 10% Owner |
Aug 31 '26 |
Sale |
3.14 |
78,145 |
245,610 |
11,599,194 |
1.15%
5.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):